GlassScriptPhysician profile
Costica Aloman
NPI 1629277652
$2,775.26
in general payments reported to CMS, 2019-2025
11 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $74.77 · 2024: $246 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,960 · Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,960.00 |
| Food and Beverage | $815.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $2,330.33 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $119.46 | 2023-2025 | |
| Abbvie INC. | $88.04 | 2024 | |
| Orphalan INC | $57.32 | 2024-2025 | Cuvrior |
| Takeda Pharmaceuticals U.S.A., INC. | $36.62 | 2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.59 | 2024 | Xifaxan, Plenvu |
| Veloxis Pharmaceuticals, INC. | $30.63 | 2025 | Envarsus |
| Madrigal Pharmaceuticals | $21.06 | 2025 | Rezdiffra |
| Ardelyx, INC. | $20.91 | 2025 | Ibsrela |
| Celltrion USA INC. | $20.22 | 2024 | Zymfentra |
| Aimmune Therapeutics, INC. | $18.08 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Costica Aloman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.